Stereotaxis | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 8.798 M

Revenue: As of FY2025 Q2, the actual value is USD 8.798 M, beating the estimate of USD 8.125 M.

EPS: As of FY2025 Q2, the actual value is USD -0.05, beating the estimate of USD -0.0667.

EBIT: As of FY2025 Q2, the actual value is USD -3.977 M.

Systems Revenue: $3.0 million for the three months ended June 30, 2025, compared to $0.2 million for the same period in 2024. For the six months ended June 30, 2025, systems revenue was $5.0 million, up from $2.9 million in 2024.
Disposables, Service, and Accessories Revenue: $5.8 million for the three months ended June 30, 2025, compared to $4.3 million in the same period in 2024. For the six months ended June 30, 2025, revenue was $11.3 million, up from $8.5 million in 2024.

Gross Margin: 52% for the three months ended June 30, 2025, down from 74% in the same period in 2024. For the six months ended June 30, 2025, gross margin was 53%, down from 64% in 2024.
Research and Development Expenses: $1.8 million for the three months ended June 30, 2025, down from $2.3 million in the same period in 2024. For the six months ended June 30, 2025, R&D expenses were $4.1 million, down from $4.5 million in 2024.
Sales and Marketing Expenses: $3.3 million for the three months ended June 30, 2025, consistent with the same period in 2024. For the six months ended June 30, 2025, sales and marketing expenses were $6.4 million, up from $6.3 million in 2024.
General and Administrative Expenses: $4.0 million for the three months ended June 30, 2025, up from $3.8 million in the same period in 2024. For the six months ended June 30, 2025, G&A expenses were $8.5 million, up from $7.2 million in 2024.
Net Loss: $3.8 million for the three months ended June 30, 2025, compared to $5.8 million in the same period in 2024. For the six months ended June 30, 2025, net loss was $9.6 million, compared to $10.3 million in 2024.

Operating Cash Flow: - $5.5 million for the six months ended June 30, 2025, compared to - $5.4 million in the same period in 2024.
Investing Cash Flow: - $0.02 million for the six months ended June 30, 2025, compared to - $0.02 million in the same period in 2024.
Financing Cash Flow: $0.07 million for the six months ended June 30, 2025, compared to $0.06 million in the same period in 2024.

Employee Retention Tax Credit: The company received approximately $0.5 million in the second quarter of 2025.

Core Business Focus: The company plans to advance the adoption of its robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received and to work with regulatory approval authorities in geographies where approval is pending. The goal is to further clinical adoption and new system placements.
Non-Core Business: The company is managing the ongoing business of Access Point Technologies EP, Inc. (APT), focusing on manufacturing, commercializing, development, and sales of APT’s catheters and related products and services. The integration of APT is expected to enhance Stereotaxis’ innovation efforts in developing a broad family of interventional devices navigated by their robots.
Priority: The company will continue to monitor the impact of the macroeconomic environment on project timing, regulatory approvals, customer and supplier operations, and operating results. They will explore financing alternatives to ensure sufficient funding for operations and capital equipment requirements.